About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely ...

In this installment of Chief Insights in Oncology, John M. Burke, MD, co-editor in chief of Targeted Therapies in Oncology, discusses his column from the September II 2025 issue.

Recent studies highlight the potential of minimal residual disease (MRD) testing to influence treatment decisions in multiple ...

Patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas (NHLs) who received frequent tests for immunoglobulin G (IgG) were less likely to experience severe infections compared with ...

Leukemia is a blood cancer that disrupts normal cell production, leading to infection risk, anemia and bleeding, and requiring tailored treatments.

Researchers at Dana-Farber Cancer Institute have developed a diagnostic tool that could transform the way acute leukemia is ...

The method, known as EVOFLUx, uses natural fluctuations in DNA methylation as a kind of molecular “barcode” to reconstruct a ...

Open-Source Hybrid Large Language Model Integrated System for Extraction of Breast Cancer Treatment Pathway From Free-Text Clinical Notes The diagnosis of chronic lymphocytic leukemia (CLL) is often ...

MONDAY, May 5, 2025 (HealthDay News) — Testing positive for leukemia actually saved the life of 51-year-old Jan Leahy, a business process owner from Wimbledon, England. Leahy benefitted from a ...